10 Best 52-Week High US Stocks to Buy

8. Spyre Therapeutics Inc (NASDAQ:SYRE)

Stock Price as of April 21: $73.39

52-Week Range: $12.28 – $75.00

Stock Upside Potential: 19.75%

Number of Hedge Fund Holders: 31

Spyre Therapeutics Inc (NASDAQ:SYRE) is among the best 52-week high US stocks to buy. On April 16, Spyre Therapeutics Inc (NASDAQ:SYRE) said in a press release that it raised around $463.5 million in gross proceeds from its recent equity offering. The company offered 7.48 million shares of its common stock, and granted the underwriters the option to purchase an additional 975,000 shares. The underwriters fully exercised their option. The shares were offered at a price of $62 apiece, near the 52-week high.

Notably, Spyre’s equity raise adds to a solid cash position. At the end of 2025, Spyre had $757 million of cash, cash equivalents, and marketable securities. The company estimated that this cash would be enough to fund its operations into the second half of 2028.

On April 13, Raymond James launched coverage of Spyre Therapeutics Inc (NASDAQ:SYRE) stock with a Strong Buy rating and a price target of $80. The firm pointed to the potential of Spyre’s clinical programs for its bullish view on the stock.

Spyre is developing next-generation, long-acting antibodies for inflammatory bowel disease and rheumatic diseases. The company says that around 2.4 million individuals in the US are diagnosed with inflammatory bowel disease. It says that more than 3 million people in the US are affected by rheumatic conditions.

Spyre has a pair of Phase 2 clinical trials in progress. Raymond James noted that proof-of-concept data readouts from these studies are expected in 2026 and 2027.

Spyre Therapeutics Inc (NASDAQ:SYRE) is a US biotechnology company based in Waltham, Massachusetts. The company is focused on developing medicines for people living with inflammatory bowel disease and rheumatic diseases. It develops advanced antibodies engineered for prolonged activity and formulated for delivery as monotherapies.